Optimizing retention, duration and discontinuation strategies for opioid use disorder pharmacotherapy (CTN-0100). August 15, 2024 to march 31, 2028. N01DA-22-2253. Task order no. 75N95024F00007…
Active Awarded Last action
- Contract number
- 75N95024F00007
- Awardee
-
The Emmes Company, LLC UEI NBQCBJ6FXBU4
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,860,579
Award facts
- Opportunity
-
- 75N95024F00007 Solicitation number
- Contract value 100% obligated
- $1,860,579.00 Current and potential, with all options
- Completion date 60% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- North Bethesda, MD 20852, USA
- Legislative mandates
-
- Service Contract Act FAR subpart 22.10
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Exercise an Option | $174,850 | |
| Change Order | $174,850 | |
| Original award | $1,510,879 |
About this award
The National Institute on Drug Abuse issued a delivery order to The Emmes Company, LLC on August 15, 2024, under the NIDA Data, Statistics, and Clinical Trial Support Center IDV (N01DA-22-2253) for optimizing retention, duration, and discontinuation strategies for opioid use disorder pharmacotherapy (CTN-0100), with a ceiling value of $1.86 million and ultimate completion date of March 31, 2028.
The NIDA Data, Statistics, and Clinical Trial Support Center is a single-award IDV valued at $44.3 million supporting data management, biostatistical analysis, clinical trial coordination, and regulatory support across substance abuse treatment trials, including opioid use disorder studies and HEAL initiative work. Place of performance is North Bethesda, Maryland. The order is priced on a cost-plus-fixed-fee basis with no set-aside.
Through fiscal year 2025, the order invoiced $203 thousand against 1.0 FTE, self-performed with no subcontractor hours reported.
Description
Optimizing retention, duration and discontinuation strategies for opioid use disorder pharmacotherapy (CTN-0100). August 15, 2024 to march 31, 2028. N01DA-22-2253. Task order no. 75N95024F00007 (TO23).
Quick answers
Who was awarded contract 75N95024F00007?
75N95024F00007 was awarded to The Emmes Company, LLC by National Institute on Drug Abuse (National Institutes of Health) on August 15, 2024.
How much is contract 75N95024F00007 worth?
The government has obligated $1,860,579 on 75N95024F00007.
Is contract 75N95024F00007 an order under another contract?
Yes. 75N95024F00007 is a delivery order under 75N95022D00017, an indefinite delivery contract.
Was contract 75N95024F00007 competed?
The extent of competition for 75N95024F00007 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award